Comments from Genomma's CEO, Marco Sparvieri
"Q1 2026 like-for-like sales declined -3.9% mainly reflecting a weak consumption environment in Mexico and continued disruptions in US Hispanic retail, partially offset by a +5.3% like-for-like increase compared to the same period last year in LatAm, where our growth initiatives are beginning to deliver encouraging results. In Mexico, sell-in declined -8.6% as trade inventory destocking continued amid broad category contractions, narrowing the sell-in/sell-out gap to 2.8 percentage points, though further adjustments may be required to offset sell-out weakness. Gross margin expanded +61 basis points to 63.4%, reflecting disciplined execution of our productivity initiatives. EBITDA margin declined -96 basis points to 22.8%, as we increased higher OpEx to support growth initiatives ahead of the expected sales ramp-up in 2H 2026. Net margin expanded +49 basis points to 11.8%, driven by lower financial expenses. We remain focused on executing our growth strategy, including product innovation, distribution expansion, enhanced in-store execution and stronger communication. While we continue to self-fund growth initiatives through productivity gains, higher opex investment is required to defend market share amid intensified competition in a weak Mexican consumption environment. We expect EBITDA margin pressures over the next three to six months, as we prioritize share defense, while growth initiatives gain traction and operating leverage improves in 2H 2026. Momentum is gradually rebuilding. While weak Mexican consumption may prolong the cycle, fundamentals remain solid and position Genomma Lab to emerge stronger."
Q1 2026 Financial Summary
The following table provides a summary of the Company's Income Statement, in millions of Mexican pesos.
Q1 2026
% sales
Q1 2025
% sales
var %
Like-for-like Sales(1)
-3.9 %
Net Sales
4,190.6
